Australia Biotechnology & Medical Research

Telix Pharmaceuticals Ltd (TLX)

Track

Track

Telix Pharmaceuticals Ltd has recorded no insider trading activity within the past three months. The most recent transactions occurred in April 2026, when MD and Group CEO Christian Behrenbruch executed multiple share purchases. Historical data indicates a pattern of acquisition by key leadership personnel over several years.
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Telix Pharmaceuticals Ltd. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Smith Darren Charlton Group Chief Financial Officer Officer
Transaction date
Purchase
Price
121.19
Quantity 86,367 -34.7%
Value US$3,237,527
Behrenbruch Christian MD & Group CEO Executive Director
Transaction date
Purchase
Price
424.64
Quantity 95,325 -26.1%
Value US$740,893
Behrenbruch Christian MD & Group CEO Executive Director
Transaction date
Purchase
Price
225.02
Quantity 17,232 -48.9%
Value US$2,781,841
Dr Christian Behrenbruch Director
Transaction date
Purchase
Price
13.91
Quantity 153,298
Value A$2,132,289
Dr Christian Behrenbruch Director
Transaction date
Purchase
Price
2.97
Quantity 120,268
Value A$356,739
Tiffany Olson Director
Transaction date
Purchase
Price
6.69
Quantity 51,305
Value A$343,385
Tiffany Olson Director
Transaction date
Purchase
Price
6.70
Quantity 10,930
Value A$73,256
Dr Christian Behrenbruch Director
Transaction date
Purchase
Price
1.09
Quantity 400,000
Value A$436,000
Dr Christian Behrenbruch Director
Transaction date
Sale
Price
7.70
Quantity 2,000,000
Value A$15,400,000
Dr Andreas Kluge Director
Transaction date
Sale
Price
7.70
Quantity 2,000,000
Value A$15,400,000
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-09-14 2026-09-07 B Purchase
Smith Darren Charlton

Group Chief Financial Officer

Officer
86,367 -34.7%
121.19
US$3,237,527 		86,367 -34.7% 121.19 US$3,237,527
2026-05-06 2026-04-29 B Purchase
Behrenbruch Christian

MD & Group CEO

Executive Director
95,325 -26.1%
424.64
US$740,893 		95,325 -26.1% 424.64 US$740,893
2026-05-06 2026-04-28 B Purchase
Behrenbruch Christian

MD & Group CEO

Executive Director
17,232 -48.9%
225.02
US$2,781,841 		17,232 -48.9% 225.02 US$2,781,841
2024-01-22 2024-01-18 B Purchase Dr Christian Behrenbruch Director
153,298
13.91
A$2,132,289 		153,298 13.91 A$2,132,289
2023-06-02 2023-05-30 B Purchase Dr Christian Behrenbruch Director
120,268
2.97
A$356,739 		120,268 2.97 A$356,739
2023-03-17 2023-03-16 B Purchase Tiffany Olson Director
51,305
6.69
A$343,385 		51,305 6.69 A$343,385
2022-12-15 2022-12-12 B Purchase Tiffany Olson Director
10,930
6.70
A$73,256 		10,930 6.70 A$73,256
2022-02-03 2022-02-03 B Purchase Dr Christian Behrenbruch Director
400,000
1.09
A$436,000 		400,000 1.09 A$436,000
2022-01-31 2022-01-27 S Sale Dr Christian Behrenbruch Director
2,000,000
7.70
A$15,400,000 		2,000,000 7.70 A$15,400,000
2022-01-31 2022-01-27 S Sale Dr Andreas Kluge Director
2,000,000
7.70
A$15,400,000 		2,000,000 7.70 A$15,400,000
Explore more

More insider trading research around Telix Pharmaceuticals Ltd

More insider trades in Australia
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in Asia-Pacific